Physician's group wants new drug labeling, 2-year DTC moratorium

Share this article:
The American College of Physicians (ACP) called for the FDA to be empowered to label newer drugs as such and to restrict consumer advertising of them.

In a policy paper titled Improving FDA Regulation of Prescription Drugs, the group, which claims a membership of 129,000 internal medicine physicians, related sub-specialists and medical students, said the agency needs more funding and greater powers. Among them, ACP argues that FDA should be authorized to require that new drugs carry labeling indicating their new-to-market status and that DTC advertising be restricted for the first two years a drug is on the market.

ACP also called for FDA to: increase their capacity to regulate drugs manufactured outside the US through appropriations and user fees; be given expanded authority in design of pre-approval trials and studies; ban “bundling of drugs that limits marketability and availability”; and improve the adverse events reporting system.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

New lipid agents are high on potency, low on doc awareness

New lipid agents are high on potency, low ...

The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...